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Introduction: Therapy options for patients with oligoprogressive malignant pleural
mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a
promising therapeutic option, as it delivers a localized ablative dose of radiation and
therefore balances efficacy and treatment related toxicities. The intent of this retrospective
analysis was to evaluate the feasibility of SBRT for limited pleural recurrences.
Methods and Materials: This retrospective single-institution study is based on the
21 consecutive patients treated with hypofractionated radiotherapy for oligoprogressive
MPM. Clinical and radiological data was collected at regular follow-up visits including
toxicity, local control and survival.
Results: At primary diagnosis, 57% of the patients presented with stage III disease.
Initial treatment of MPM consisted of induction chemotherapy (n = 12) prior to a
macroscopic complete resection (n= 18). Three patients received additional intracavitary
chemotherapy and another three patients were treated with chemotherapy alone without
another treatment at the time of first diagnosis. A total of 50 lesions in recurrent MPMwere
treated with SBRT. The median number of radiotherapy fractions was 5 (range 3–20) with
a median dose per fraction of 5Gy (range 2.5–12.5Gy). The median total treatment dose
was 30Gy (20–50Gy) with a median prescription isodose line (IDL) of 65% (65–100%).
Median follow-up of all patients from diagnosis was 28 months (range 7–152 months).
Analyzing all lesions separately, the 12-months-local control from SBRT was 73.5%. The
median progression free survival (PFS) after SBRT was 6 months (range 0–21 months)
and the median OS from first first SBRT was 29 months (range 0–61 months). Only one
patients experienced above Grade 3 toxicities.
Conclusion: This analysis demonstrates the feasibility of a SBRT approach for
oligorecurrent MPM. SBRT was well-tolerated even after multiple repetitions and local
control was high with a promising median OS.
Keywords: SBRT, malignant pleural mesothelioma, local recurrence, oligoprogression, retrospective analysis
Schröder et al. SBRT for Oligorecurrent Pleural Mesothelioma
INTRODUCTION
Malignant pleural mesothelioma (MPM) still has a
devastating prognosis. Even after recent advances in therapy
options within a multi-modality therapy setting combining
chemo- and/or radiotherapy to mesothelioma resection, the
median survival is up to 23 months (1–5).
The main limiting factor until today is a high local recurrence
pattern for this disease. Due to anatomical restraints, microscopic
tumor burden will be eventually left behind even after radical
surgery. The role of adjuvant radiotherapy in this setting remains
unclear. Although in-vivo, MPM cell lines shown a great variety
of radiosensitivity, including highly radiosensitive lines, data
regarding clinical outcome remains inconclusive (6–9).
In case of recurrent disease after initial multimodal
treatment, standardized treatment recommendations for
effective salvage strategies treatment are needed. According
to ASCO guidelines, radiation therapy may be offered to
patients with localized asymptomatic recurrence (moderate
strength of recommendation). The dosage of fractionated
radiotherapy depends on the site and extent of disease and
should be discussed on an individual basis (10). Especially
patients with very limited local pleural recurrences represent a
challenge, as the optimal treatment strategy balancing toxicity
and efficacy has not been defined yet (11). These patients may be
candidates for a local ablative treatment and may benefit from an
extended progression free survival (PFS) until systemic therapy
is indicated. Stereotactic body radiotherapy (SBRT) might be
a promising option for these patients since it delivers a local
ablative biologic dose of radiation and was recently explored
in the oligoprogressive setting of solid tumors with excellent
local control rates, encouraging outcome, and low severe toxicity
(12, 13). The benefit of locally ablative therapy could be shown
for other tumor entities, e.g., by Gomez et al. in patients with
stage IV non small cell lung cancer (NSCLC) with up to three
metastases or Palma et al. in patients with up to five metastases
of different primary tumors. Both could show a statistically
significant improvement in overall survival by the use of SBRT,
e.g., 41.2 months vs. 17 months for Gomez et al. (14, 15).
The intent of this retrospective analysis was to evaluate the
feasibility of a novel strategy to integrate SBRT as first salvage
therapy for limited pleural recurrences in pleural mesothelioma.
METHODS AND MATERIALS
Patient Characteristics
Our instituitonal database lists patients since 1999 and is
simultaneously of prospective nature.
Between 2010 and 2018, 21 patients with the
histo-pathological diagnosis of MPM were treated
with hypofractionated radiotherapy for thoracic
oligometastatic progression.
Most patients initially presented with IMIG stage III disease
(57%). Only one patient had distant metastases upon first
diagnosis. The median age at first diagnosis was 65 years with a
range from 33 to 75 years.
TABLE 1 | Patient characteristics.
n %
Sex
Male 17 81
Female 4 19
Histology
Epithelioid 17 81
Sarcomatoid 2 9.5
Biphasic 2 9.5
Imig stage
I 3 14.3
II 4 19
III 12 57.1
IV 2 9.5
Pre-SBRT therapy modalities
Induction systemic
therapy
12 67
Surgical resection 18 86
Intracavitary
chemotherapy
3 25
Systemic therapy alone 3 14
Total 21 100
For initial treatment of MPM, 18 patients (ECOG 0-1)
had received a macroscopic complete resection (MCR), of
which 12 patients received systemic induction (platinum based)
therapy prior to the surgical resection. Three patients were
treated with chemotherapy alone without any other treatment.
MCR consisted of (extrapleural) pleurectomy/decortication
and one pleurectomy. In some cases additional intracavitary
cisplatin/fibrin application was performed within our clinical
phase I/II trial (Intracavitary Cisplatin-Fibrin Localized
Chemotherapy after Pleurectomy/Decortication for the
Treatment of Patients with Malignant Pleural Mesothelioma
(INFLuenCe-Meso I/II). Further patient characteristics are
shown in Table 1.
Radiation Treatment Planning and Delivery
Planning CT was acquired as 4D-CT with retrospective
amplitude-based image sorting. In addition, a 3D-CT was
performed in free breathing to allow for contrast i.v. injection.
Gross tumor volume (GTV) was contoured as the visible
tumor in the planning CT supplemented by information from
i.v. contrast 3D-CT or further imaging including FDG-PET or
magnetic resonance imaging (MRI) if available. In FDG-PET CT
scans, the FDG active lesions with an visible correlate in the i.v.
CT scans were contoured. No additional clinical target volume
(CTV) margin was added (i.e., GTV= CTV).
The internal target volume (ITV) was generated as
a composite GTV from the different amplitude-based
reconstructed CT scans complemented by a margin of 5mm
to derive the planning target volume (PTV). Treatment
planning and delivery was done with either conformal or
intensity-modulated (VMAT) techniques.
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All plans were calculated by a radiation therapy technologist
using common constraints for the organs at risk and target
prescription standards and were multidisciplinary reviewed. For
treatment planning, Eclipse softwareTM (Varian medical systems)
was used. Patients were treated with either 6 or 18MV. If
necessary immobilization by individualized vacuum cast or
abdominal compression was used.
Endpoints and Toxicity Definitions
During treatment, all patients were monitored daily for acute
treatment related toxicity. Follow-up 6 weeks after completion
of SBRT and every 3–4 months thereafter included physical
examination and CT, PET-CT and/or MRI scans until tumor
progression. Toxicity was scored according to the National
Cancer Institute for Common Terminology Criteria for Adverse
Events (CTCAE) v5.0 criteria. Local failure of a metastatic lesion
was defined as either reappearance after complete remission
or re-growth after initial partial response on follow-up CT or
MRI scans.
Statistical Analysis
Overall survival and PFS were calculated according to the
Kaplan-Meier method. Overall survival (OS) was calculated from
first diagnosis until death or last follow-up, PFS from SBRT until
tumor relapse or last follow-up. Regarding radiation treatment
parameters, descriptive statistics were calculated. Additionally,
the biological effective dose (BED) as well as the 2-Gy equivalent
dose (EQD2) were calculated according to the linear-quadratic
(LQ) formalism using an alpha-beta for tumor tissue of 10Gy.
For statistical analysis, SPSS version 25 was used.
RESULTS
Radiation Therapy
A total of 21 patients received 1 course of radiation treatment,
10 of those received a second and 4 a third course of RT. A total
of 50 lesions in recurrent MPM were treated with SBRT. The
median number of PTVs treated during a course was 1 (range
1–3). 75 to 100% were treated with a locally ablative dose in an
oligorecurrent setting at all courses, but up to 25% of patients
were also treated with a palliative analgetic approach. Two
patients received concurrent systemic therapy (Pembrolizumab).
The median time between diagnosis of MPM and first radiation
treatment was 15 months (range 5–90 months).
The median number of fractions at all courses was 5 (range 3–
20) with a median prescription dose per fraction of 5Gy (range
2.5–12.5Gy). The median total prescription dose was 30Gy
(20–50Gy) with a median prescription isodose line (IDL) of
65% (65–100%).
The median PTV volume of all lesions was 40.1 cc (range
3.3–774.3 cc). The median EQD2 (2-Gy-eqivalent dose) was
44.87Gy (range 23.49–88.34Gy). A detailed overview of the
radiotherapy treatment parameters separately by RT courses are
shown in Table 2. If there were multiple lesions treated at one
timepoint the sum plan of all lesions was used if they were in
relevant proximity.
Clinical Outcome
Median follow-up of all patients from diagnosis on was 28
months (range 7–152months). At the time of analysis, 11 patients
were still alive.
Local Control and Pattern of Progression
Intrathoracic out-of-field or in-field recurrence after SBRT was
observed in up to 62% of patients. After the first course of SBRT,
a total of 13/21 patients had a thoracic recurrence (11 out-of-
field, 2 in-field). After the second and third course the number of
patients with thoracic recurrence was 6/10 and 2/4, respectively
(each with 50% in-field-recurrence).
When looking at all lesions separately the 12-months-local
control of the irradiated lesions was 73.5%. Figure 1 shows the
local control after repeated courses of SBRT and Figure 2 the
patterns of failure.
Patients with a recurrence after the first SBRT received
a variety of treatment modalities. Most patients received
another SBRT (54%) and /or systemic therapy (38%). One
patient received a pleurectomy/decortication. In case of
another recurrence, most patients were treated with systemic
therapy (86–100%).
PFS and OS
The median PFS after first SBRT was 6 months (range 0–21
months) and the median OS after first SBRT was 29 months
(range 0–61 months). The OS at 3 years was 9.5%. Figures 3, 4
show the PFS and the OS from first SBRT.
Toxicity
Overall, the radiation treatment was very well-tolerated. Only
1 patient experienced ≥ Grade 3 toxicity. This patient whose
MPM was infiltrating the esophagus and who received RT of
the esophagus and mediastinal lesions was hospitalized during
treatment due to upper gastrointestinal bleeding. The same
patient died 3 months later due to massive esophageal bleeding
and progressive disease.
DISCUSSION
In this retrospective single institution study, we analyzed the
feasibility of SBRT as a salvage procedure in 21 patients
with oligoprogressive MPM. Therapy options for patients with
oligoprogressive malignant pleural mesothelioma (MPM) are
limited. However, there is few data about SBRT as a salvage
strategy for oligoprogressive MPM. Oligoprogression, wheter in
MPM or otherwise, is not consistently defined throughout the
literature. For our analysis, we specified it as a maximum of
three lesions. SBRT is a promising treatment option in this
setting as it delivers a local ablative radiation dose as recently
explored in an oligometastatic setting of solid tumors with
excellent local control rates, encouraging outcome, and low
severe toxicity (14–18).
In our cohort, patients were treated with a median EQD2
of 44.87 Gy10. Local control was very promising with a 12-
months local control of the irradiated lesions of 73.5%. The
applied radiation doses were not in the range of the ablative doses
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TABLE 2 | Dosimetric parameters of RT courses.
RT course 1st 2nd 3rd
PTV Median Range Median Range Median Range
Volume (cc) 47.8 3.3–754.2 29.8 4.9–264.00 432.65 38.60–774.30
Dose/fraction mean (Gy) 6.6 2.5–14.45 6.3 2.55–13.87 3 2.61–9.14
Total dose mean (Gy) 38.22 20.11–50.00 32.32 30.00–57.50 33.69 30.00–45.70
BED mean (Gy) 56.82 28.19–106.00 51.35 38.45–99.37 43.19 39.00–87.48
EQD2 mean (Gy10) 47.35 23.49–88.34 42.79 32.04–82.81 35.99 32.5–72.90
FIGURE 1 | Local control for all lesions after repeated courses of SBRT.
FIGURE 2 | Patterns of failure after repeated courses of SBRT for oligometastatic recurrence.
applied in phase I or II studies regarding oligometastatic lesions
of other primary disease. In the NRG-BR001 and SABR-COMET
trials, the treatment dose was 30–50Gy in 3–5 fractions and
30–60Gy in 3–8 fractions, respectively (15, 17). Nevertheless, the
local control in our patient cohort appears to be very promising.
Regarding SBRT in MPM patients there is only one case report
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FIGURE 3 | Progression free survival after first SBRT (months, n = 21).
FIGURE 4 | Overall survival after first SBRT (months, n = 21).
about a patient receiving Cyberknife treatment (70 Gy/5 fx) for a
focal paravertebral recurrence after MCR inMPMwho remained
disease-free at 40 months (19). Additionally, two case series exist
about patients receiving palliative stereotactic IMRT by Munter
et al., but not for an oligoprogressive setting as in our cohort
(20, 21).
Looking at efficacy, although our results are promising, there
are certainly challenges regarding the definition for an optimal
target volume. Even with PET-CT based planning, lesions
might be missed or underestimated due to the disease‘s nature,
respectively its infiltrating pattern. Hence, not all of the lesions
might be covered with a sufficient dose, resulting in recurrences.
The close neighborhood to abdominal organs at risk (OARs),
especially if targeting lesions close to the diaphragm, might also
lead to dose compromises in the target volume necessary for
sparing the OAR.
When looking at safety, our toxicity profile with only 1 patient
experiencing ≥ grade 3 toxicity due to esophagus infiltration is
promising. The patient was hospitalized during treatment due
to resulting upper gastrointestinal hemorrhage and eventually
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died of a massive bleeding later on. We interpreted this as a
combination of the local radiation therapy in addition to the
infiltrating and progressive disease. There were no signs of any
severe pneumonitis in our cohort.
Due to the high local control, promising OS and low toxicity
profile we propose that SBRT may be a promising approach
to provide effective local control in a short overall treatment
time to delay systemic therapy until further progression in
selected patients.
We are aware of the limitation of this case series concerning
the inhomogeneity of the patient cohort with their different
therapies applied beforehand and divergent time points of
radiotherapy. Nevertheless, oligoprogression is observed in
MPM and SBRT appears to be feasible and safe, especially for
patients with a reduced general condition after multiple previous
therapies. Further studies are needed to determine the role of
SBRT and should focus on optimizing fraction schemes as well
as exploring the influence on the patient’s quality of life.
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